Pemetrexed in advanced non-small cell lung cancer (Q34160513)

31 July 2017

1 reference

title

Pemetrexed in advanced non-small cell lung cancer (English)

1 reference

31 July 2017

1

Cesare Gridelli

1 reference

31 July 2017

Paolo Maione

2

1 reference

31 July 2017

Antonio Rossi

3

1 reference

31 July 2017

Maria Anna Bareschino

4

1 reference

31 July 2017

Clorinda Schettino

5

1 reference

31 July 2017

Paola Claudia Sacco

6

1 reference

31 July 2017

Rosario Zeppa

7

1 reference

31 July 2017

language of work or name

English

0 references

publication date

25 January 2011

1 reference

Expert Opinion on Drug Safety

31 July 2017

1 reference

31 July 2017

10

1 reference

31 July 2017

311-317

1 reference

31 July 2017

2

1 reference

Global cancer statistics, 2002

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.553281

10.1517/14740338.2011.553281

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference